ClinicalTrials.gov record
Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women
ClinicalTrials.gov ID: NCT00277914
Public ClinicalTrials.gov record NCT00277914. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
12-month Sustained Efficacy of Flibanserin v Placebo n Younger Women With HSDD in NA
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To estimate the duration of efficacy with continued treatment of double-blind flibanserin or placebo over twenty-four weeks of treatment.
Study identification
- NCT ID
- NCT00277914
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 749 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 45 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2006 (Type not available)
- Primary completion
- Jul 2007 (Actual)
- Completion
- Not listed
- Last update posted
- Mar 16, 2012
Started 2006
United States locations
- U.S. sites
- 55
- U.S. states
- 32
- U.S. cities
- 55
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 511.74.01051 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 511.74.01027 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 511.74.01029 Boehringer Ingelheim Investigational Site | Scottsdale | Arizona | — | — |
| 511.74.01031 Boehringer Ingelheim Investigational Site | Tucson | Arizona | — | — |
| 511.74.01004 Boehringer Ingelheim Investigational Site | Jonesboro | Arkansas | — | — |
| 511.74.01053 Boehringer Ingelheim Investigational Site | Little Rock | Arkansas | — | — |
| 511.74.01033 Boehringer Ingelheim Investigational Site | Palm Springs | California | — | — |
| 511.74.01003 Boehringer Ingelheim Investigational Site | Palo Alto | California | — | — |
| 511.74.01015 Boehringer Ingelheim Investigational Site | Sacramento | California | — | — |
| 511.74.01013 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 511.74.01052 Boehringer Ingelheim Investigational Site | Torrance | California | — | — |
| 511.74.01022 Boehringer Ingelheim Investigational Site | Aurora | Colorado | — | — |
| 511.74.01046 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 511.74.01002 Boehringer Ingelheim Investigational Site | Groton | Connecticut | — | — |
| 511.74.01023 Boehringer Ingelheim Investigational Site | Middlebury | Connecticut | — | — |
| 511.74.01009 Boehringer Ingelheim Investigational Site | West Hartford | Connecticut | — | — |
| 511.74.01035 Boehringer Ingelheim Investigational Site | Newark | Delaware | — | — |
| 511.74.01039 Boehringer Ingelheim Investigational Site | Coral Gables | Florida | — | — |
| 511.74.01019 Boehringer Ingelheim Investigational Site | Gainesville | Florida | — | — |
| 511.74.01044 Boehringer Ingelheim Investigational Site | Hollywood | Florida | — | — |
| 511.74.01001 Boehringer Ingelheim Investigational Site | Hudson | Florida | — | — |
| 511.74.01043 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| 511.74.01032 Boehringer Ingelheim Investigational Site | St. Petersburg | Florida | — | — |
| 511.74.01036 Boehringer Ingelheim Investigational Site | Roswell | Georgia | — | — |
| 511.74.01047 Boehringer Ingelheim Investigational Site | Champaign | Illinois | — | — |
| 511.74.01038 Boehringer Ingelheim Investigational Site | Evansville | Indiana | — | — |
| 511.74.01014 Boehringer Ingelheim Investigational Site | Lexington | Kentucky | — | — |
| 511.74.01007 Boehringer Ingelheim Investigational Site | Baton Rouge | Louisiana | — | — |
| 511.74.01024 Boehringer Ingelheim Investigational Site | Rockland | Maine | — | — |
| 511.74.01030 Boehringer Ingelheim Investigational Site | Ann Arbor | Michigan | — | — |
| 511.74.01056 Boehringer Ingelheim Investigational Site | Bingham Farms | Michigan | — | — |
| 511.74.01010 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 511.74.01012 Boehringer Ingelheim Investigational Site | Billings | Montana | — | — |
| 511.74.01045 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 511.74.01041 Boehringer Ingelheim Investigational Site | Las Vegas | Nevada | — | — |
| 511.74.01055 Boehringer Ingelheim Investigational Site | Reno | Nevada | — | — |
| 511.74.01018 Boehringer Ingelheim Investigational Site | Poughkeepsie | New York | — | — |
| 511.74.01011 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 511.74.01048 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 511.74.01021 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 511.74.01042 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 511.74.01050 Boehringer Ingelheim Investigational Site | Edmond | Oklahoma | — | — |
| 511.74.01006 Boehringer Ingelheim Investigational Site | Eugene | Oregon | — | — |
| 511.74.01034 Boehringer Ingelheim Investigational Site | Medford | Oregon | — | — |
| 511.74.01040 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 511.74.01017 Boehringer Ingelheim Investigational Site | Anderson | South Carolina | — | — |
| 511.74.01057 Boehringer Ingelheim Investigational Site | Knoxville | Tennessee | — | — |
| 511.74.01008 Boehringer Ingelheim Investigational Site | Nashville | Tennessee | — | — |
| 511.74.01016 Boehringer Ingelheim Investigational Site | Plano | Texas | — | — |
| 511.74.01020 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 511.74.01005 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| 511.74.01026 Boehringer Ingelheim Investigational Site | Norfolk | Virginia | — | — |
| 511.74.01037 Boehringer Ingelheim Investigational Site | Renton | Washington | — | — |
| 511.74.01028 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 511.74.01049 Boehringer Ingelheim Investigational Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00277914, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2012 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00277914 live on ClinicalTrials.gov.